Yolanda González - Concepedia

Author

Yolanda González

Hospital Universitari de Girona Doctor Josep Trueta ORCID

Also Known As

Cristina Motlló, I. Gonzalez Gallego, Immaculada Gonzalez Gallego, L Palomera, Y GONZALEZ, Y Gonzalez, Y González, Y. Gonzalez, Y. Gonzalez Irazabal, Y. González

148

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitari de Girona Doctor Josep Trueta Hospital Clínico San Carlos Hospital Universitario Ramón y Cajal Hospital General Universitario Morales Meseguer Hospital Clínico Universitario de Valencia

About

Yolanda González is an author at Hospital Universitari de Girona Doctor Josep Trueta specializing in medicine, health sciences, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.2K
2	Health Sciences	7	7	206
3	Public Health	3	3	194
4	Allergy	1	1	35
5	Allergy Medicine	1	1	35

Yolanda González

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, The Lancet Oncology Hematological MalignancyElderly PatientsMedicineRandomised TrialHematology	2010	459
Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project David McHugh, Cynthia A. Cameron, José E. Abdenur, Genetics in Medicine Metabolic SyndromeNewborn ScreeningMetabolic DisorderMass SpectrometryPediatrics	2011	349
The impact of COVID-19 on patients with asthma José Luís Izquierdo, Carlos Almonacid, Yolanda González, European Respiratory Journal	2020	230
Updating of normal levels of copper, zinc and selenium in serum of pregnant women Silvia Izquierdo Álvarez, Sandra García Castañón, Maria Luisa Calvo Ruata, Journal of Trace Elements in Medicine and Biology InfertilitySelenium DeficiencyNormal LevelsGynecologyPregnancy	2007	137
Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia Francesc Bosch, Pau Abrisqueta, Neus Villamor, Journal of Clinical Oncology	2009	127
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Leukemia Hematological MalignancyTransplantationMarrow TransplantationOncologyPethema/gem Trial	2017	67
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia Pau Abrisqueta, Neus Villamor, María José Terol, Blood	2013	60
Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study Daysis Yoe-Ling Chang-Chan, Rafael Ríos, Miguel Rodríguez‐Barranco, Clinical & Translational Oncology Hematological MalignancyEpidemiologyMedicineEpidemiology Of CancerHematology	2021	37
The impact of COVID-19 on patients with asthma José Luís Izquierdo, Carlos Almonacid, Yolanda González, AsthmaArtificial IntelligenceEnvironmental AllergyInflammatory Lung DiseaseLung Inflammation	2020	35
A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib Laura Rosiñol, María Teresa Cibeira, María‐Victoria Mateos, Blood	2010	33

Page 1